A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
Inorganic Chemistry Frontiers · 2025 · 12 (12) · 3981-3987
DOI: 10.1039/d5qi00605h ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry Frontiers, 2025. Verfasst von Jiaqian Xu und 5 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Research Grants Council, University Grants Committee, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission.
Abstract (Originalsprache)
PROTAC–Pt( iv ) represents a new class of dual-action Pt( iv ) prodrugs integrating platinum drugs with PROTAC-mediated protein degradation, exhibiting superior antitumor efficacy compared to conventional Pt( iv ) prodrug and PROTAC alone in vivo .
Förderung
- Research Grants Council, University Grants Committee
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Commission
- City University of Hong Kong
Zitieren
APA
Xu, J., Chen, S., Ng, K., Chen, X., Fu, W. C., & Zhu, G. (2025). A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy. Inorganic Chemistry Frontiers, 12(12), 3981-3987. https://doi.org/10.1039/d5qi00605h
Vancouver
Xu J, Chen S, Ng K, Chen X, Fu WC, Zhu G. A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy. Inorganic Chemistry Frontiers. 2025;12(12):3981-3987. doi:10.1039/d5qi00605h
BibTeX
@article{Xu2025,
author = {Xu, Jiaqian and Chen, Shu and Ng, Ka-Yan and Chen, Xianfeng and Fu, Wai Chung and Zhu, Guangyu},
title = {A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy},
journal = {Inorganic Chemistry Frontiers},
year = {2025},
volume = {12},
number = {12},
pages = {3981--3987},
doi = {10.1039/d5qi00605h}
}
EUVIMED